English
Language31 languages
EnglishEnglishDeutschGermanالعربيةArabicFrançaisFrenchEspañolSpanishPortuguês (Brasil)Brazilian PortugueseItalianoItalian日本語Japanese한국어KoreanРусскийRussianTürkçeTurkishفارسیPersian (Farsi)עבריתHebrewҚазақшаKazakhPolskiPolishNederlandsDutchRomânăRomanianČeštinaCzechΕλληνικάGreekMagyarHungarianBahasa IndonesiaIndonesianहिन्दीHindiاردوUrduBahasa MelayuMalayไทยThaiУкраїнськаUkrainianO‘zbekchaUzbekTiếng ViệtVietnamese繁體中文Traditional ChineseDanskDanishSvenskaSwedish

Supported languages are prioritized from the country mix of past inquiries. If you would like another language, please send us feedback.

Growth-hormone axis research

Hexarelin Acetate

Stereochemically defined GHSR agonist hexapeptide (hexarelin/examorelin)

Per batch COACAS 140703-51-1RUO
Batch COA
MOQ1 kit (10 vials) per SKU
Supplied formAmidated six-residue peptide with D-2-methyltryptophan and D-phenylalanine
Lead timeConfirmed with quote
Hexarelin Acetate — Lyophilized material; confirm released-lot appearance on the COA
Hexarelin Acetate — Lyophilized material; confirm released-lot appearance on the COA · Representative packaging image · verify the ordered lot
Representative packaging image · verify the ordered lot

Decision summary

Key benefits

  • Research value: a compact stereochemically defined GHRP enables studies of GHSR signaling, GH-response pharmacology, receptor desensitization, CD36 binding and model-specific cardiovascular, mitochondrial or stress-response pathways
  • These research contexts do not establish therapeutic benefit, athletic performance, recovery or body-composition effects for an RUO lot.
Published research context is presented for literature orientation only. It is not a dosing, treatment or human-use instruction.

Qualification data

Specifications to confirm against the released lot

CAS
140703-51-1
Formula
Confirm supplied form on batch COA
Molecular weight
887.04 g/mol
Appearance
Lyophilized material; confirm released-lot appearance on the COA
Purity
Per batch COA
Storage
Use the released-lot COA and stability statement for the supplied acetate/counterion state. Define temperature, moisture and light protection, container closure, freeze-thaw allowance, solvent and concentration; do not infer solution life from generic vendor claims.
MOQ
1 kit (10 vials) per SKU
Lead time
Confirmed with quote

Qualification matrix

Identity, purity and content are separate release questions.

Identity

Confirm the stated molecule and supplied form. Start with the matching batch COA; request sequence-level evidence only when the buyer's written procedure requires it and availability or a separate scope has been agreed.

Purity

Review RP-HPLC method conditions, wavelength, integration and related-peak handling. A percentage without the method is not enough.

Content

Net peptide content is not the same as gross lyophilized powder weight. Ask which assay supports the stated amount and whether water/counter-ion is addressed.

Stability

Follow the storage condition stated on the batch COA or label from receipt onward.

Research context

What researchers study about Hexarelin Acetate

Hexarelin (examorelin) is the synthetic amidated hexapeptide H-His-D-Trp(2-Me)-Ala-Trp-D-Phe-Lys-NH2 and a growth-hormone secretagogue receptor agonist studied in early endocrine pharmacology. PubChem CID 6918297 defines the free-peptide record. Cardiovascular research identifies CD36 binding and GHSR-related effects in animal and tissue models, while muscle and neuroprotection studies remain preclinical. Hexarelin is not an FDA-approved drug. WADA's 2026 Prohibited List names examorelin (hexarelin) among GH-releasing peptides prohibited at all times for athletes subject to the Code. This catalog material is an RUO analytical/research reagent, not a finished dosage form.

  • Evidence contexts include GHSR-mediated endocrine signaling and GH response in early human studies
  • CD36/GHSR cardiovascular mechanisms in animal and tissue models; and exploratory muscle-mitochondrial and cellular stress-response research
  • Model evidence must not be represented as human cardioprotection, neuroprotection, recovery or metabolic benefit.

Mechanism context

The question the literature is testing

Hexarelin acts as a growth-hormone secretagogue receptor agonist in endocrine systems, with downstream signaling that promotes GH release. A 2002 Circulation Research study identified CD36 as a cardiac hexarelin-binding protein and showed CD36-dependent coronary vasoconstrictive responses in perfused animal hearts. Separate rat ischemia-reperfusion work reported injury-marker changes that were blocked by a GHSR antagonist. These model-specific findings support more than one target hypothesis but do not establish a single human cardioprotective mechanism.

Evidence map

Research routes and exposure context

Evidence tierApproved finished-product context
Routes reported in sources
No administration route applies
Dose / exposure contextProtocol-specific; verify the cited primary source
Routes and exposure contexts summarize cited studies or approved finished-product labels. They are not instructions for administering this RUO material; no customer dose is provided.

Evidence boundaries

Compatibility, limitations and decision context

  • Hexarelin is not FDA approved
  • Early human endocrine studies and preclinical literature do not establish long-term safety or clinical benefit for independently supplied material
  • WADA lists examorelin (hexarelin) as prohibited at all times for athletes subject to the Code

Interactions reported in the literature

  • No stacking or combination-use guidance is provided
  • Any combination experiment requires a prespecified protocol, controls, concentration justification and institutional risk review; vendor pairing claims are not evidence.
Literature context is not a supplier release result or human-use instruction. Follow your institution's approved laboratory risk assessment.

Batch documentation

Hexarelin Acetate batch COAs

Laboratory: Manufacturer's QC laboratoryTests: HPLC purity · MS identity · endotoxin · fill amount

  • Blurred preview of a Hexarelin Acetate 2 mg batch COA2 mg
  • Blurred preview of a Hexarelin Acetate 5 mg batch COA5 mg

Previews are blurred on purpose so the documents cannot be reused; third-party reports show their first page only. Sales sends the clear full version for the product and strength you ask about.

Independent test fails? Full refund.

Representative records, refreshed periodically

Published COAs show recent representative batches and may not be the newest. For a quote or shipment, sales confirms the lot and sends its COA.

Third-party reports, added progressively

Previews of the first page of third-party reports are on our Quality page and on the matching product pages; sales sends the full report on request. You can also send any vial from your order to an independent laboratory of your choice. Unless agreed otherwise in writing, the buyer pays for optional testing.

Help reviewing your COA

Need help reading a batch COA or third-party report? Sales can explain the test items, specifications and how the results relate to the lot under discussion.

On every batch COA: HPLC purity · MS identity · endotoxin · fill amount · Verify LyoPep

Ask for the current packet, not a generic certificate

  • Require the stereochemically defined complete sequence and terminal amidation, high-resolution intact mass, an orthogonal identity method, peptide-content assay, chromatographic purity with impurity assignment, counterion/acetate quantitation, water, residual solvents and aggregate assessment
  • A nominal >98% HPLC area result, vial appearance or CAS number alone does not establish content or salt composition.
Batch COA for the released lotHPLC purity with method contextMS identity resultEndotoxin resultFill amount (measured content per vial)SDS and handling statement

Available fills

Quote the fill and pack configuration you need

Reference SKUFillBase pack
HX22 mg10 vials
HX55 mg10 vials

Handling

Plan storage before the parcel arrives

Use the released-lot COA and stability statement for the supplied acetate/counterion state. Define temperature, moisture and light protection, container closure, freeze-thaw allowance, solvent and concentration; do not infer solution life from generic vendor claims.

State the destination and timing so receipt can be planned, then move the material into its stated storage condition on arrival.

Buyer FAQ

Terms to settle before the purchase order

Can a buyer arrange third-party testing?+

Yes. You can send any vial from your order to an independent laboratory of your choice. If you want the laboratory, specification, sampling, method and acceptance rule agreed with us before testing, sales confirms them in writing. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

What if my own lab test shows the product is out of specification?+

Send any vial from your order to an independent laboratory of your choice. If the report shows the product does not meet the specification on its COA — purity below the stated minimum, or an identity that does not match — share the report with our sales team and we refund that product in full.

Does HPLC purity prove peptide content?+

No. Chromatographic purity describes the relative peak profile under a stated method. Identity, water, counter-ion, residual solvents and assay/content may require separate methods.

How should material be stored after delivery?+

Move it into the storage condition stated on the batch COA or label as soon as it arrives, and record the package condition on receipt.

How are payment terms handled?+

Available methods and milestones depend on order value, destination and project type. The pro forma invoice should state currency, bank details, fees, payment milestones and the release condition.

Why must the testing laboratory understand peptide chemistry?+

Free-base and salt forms, hydrophilic and hydrophobic sequences, aggregation and adsorption can change sample preparation and method suitability. Use a laboratory experienced with the molecule class.

External qualification references

WHO good storage and distribution practices ISO/IEC 17025 laboratory competence 21 CFR 211.84 component testing and supplier COA controls
These are buyer-qualification references, not claims that this RUO material is regulated, certified or released under those frameworks. Applicability depends on the buyer's workflow and jurisdiction.

Selected sources

Literature behind the research context

  • Key primary sources: PubChem CID 6918297; WADA 2026 Prohibited List; Deghenghi et al. 1994 (PMID 8028453); Ghigo et al. 1994 (PMID 8126144); Imbimbo et al. 1994 (PMID 7957536); Loche et al. 1995 (PMID 7673411); Torsello et al. 1996 (PMID 8921832); Bodart et al. 1999 (PMID 10532947); Bodart et al. 2002 (PMID 11988484); Mao et al. 2014 (PMID 25278975); the cited 2017 ischemia-reperfusion and cachexia studies; and Meanti et al. 2023 (PMID 36674509). Human, animal and cell evidence are labelled separately in the literature section.
  1. 01

    GH-releasing activity of hexarelin, a new growth hormone releasing peptide, in infant and adult rats

    Life Sciences · 1994 · peer-reviewed original research (foundational discovery paper)

    Open source
  2. 02

    Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man

    Journal of Clinical Endocrinology & Metabolism · 1994 · peer-reviewed original research (clinical pharmacology, dose/route comparison)

    Open source
  3. 03

    Mechanism of action of Hexarelin. I. Growth hormone-releasing activity in the rat

    European Journal of Endocrinology · 1996 · peer-reviewed original research (mechanism of action)

    Open source
  4. 04

    The effect of hexarelin on growth hormone (GH) secretion in patients with GH deficiency

    Journal of Clinical Endocrinology & Metabolism · 1995 · peer-reviewed original research (clinical trial, GH deficiency)

    Open source
  5. 05

    Does desensitization to hexarelin occur?

    Growth Hormone & IGF Research · 1998 · peer-reviewed original research (tachyphylaxis/desensitization study)

    Open source
  6. 06

    Identification and characterization of a new growth hormone-releasing peptide receptor in the heart

    Circulation Research · 1999 · peer-reviewed original research (receptor pharmacology)

    Open source
  7. 07

    CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart

    Circulation Research · 2002 · peer-reviewed original research (receptor identification, landmark mechanism paper)

    Open source
  8. 08

    GH-independent cardiotropic activities of hexarelin in patients with severe left ventricular dysfunction due to dilated and ischemic cardiomyopathy

    European Journal of Heart Failure · 2002 · peer-reviewed original research (human clinical study, cardiac patients)

    Open source

Product FAQ

Questions buyers ask about Hexarelin Acetate

What identity details should an order specification include for Hexarelin Acetate?+

Specify the complete stereochemical sequence H-His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH₂, C-terminal amidation and the required counterion state. PubChem CID 6918297 and CAS 140703-51-1 describe the free-peptide record; an acetate-labelled lot can have a different gross composition. The batch documents should report peptide content and measured acetate or other counterions rather than relying on the product name or CAS alone.

Which batch tests are especially important for Hexarelin?+

Request high-resolution intact mass, an orthogonal identity or sequence method capable of confirming the two D-residues and 2-methyltryptophan, terminal-amidation confirmation, chromatographic purity with impurity assignment and a separate peptide-content assay. Also define acetate or other counterions, water, residual solvents, storage and retest conditions. HPLC area purity and vial appearance alone do not establish stereochemical identity, peptide content or salt composition.

Evidence before order

Buyer intelligence

Related research materials

Compare adjacent molecules and documentation needs.

Full catalog
Growth-hormone axis research

Sermorelin

Amidated human GHRH(1-29) research reference

Purity
Lot-specific · Batch COA
CAS
86168-78-7
Lyophilized powderNasal spray availableCapsules available
Growth-hormone axis research

GHRP-2

Pralmorelin (GHRP-2) hexapeptide research reference · approved Japanese diagnostic product context is not transferable

Purity
Lot-specific · Batch COA
CAS
158861-67-7
Lyophilized powderNasal spray available
Growth-hormone axis research

Tesamorelin 10mg + Ipamorelin 5mg

Tesamorelin–ipamorelin two-component research blend · “IP5” shorthand is not inositol pentaphosphate

Purity
Component-specific · Batch COA
CAS
218949-48-5
Lyophilized powder
Growth-hormone axis research

AOD9604

Modified human-growth-hormone fragment 176–191 · investigational metabolic research peptide

Purity
Target ≥ 99.0% · Batch COA
CAS
221231-10-3
Lyophilized powderNasal spray available